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Meloxicam (MEL) could relieve acute pain by absorbing through a highly vascularized 
alternative route: the nasal mucosa. However, there is an issue that requires a solution: the 
poor water-solubility of MEL. Chitosan can help to overcome this problem and because it is 
mucoadhesive, capable of opening the epithelial tight junctions and can achieve controlled 
drug delivery, there is a growing interest in it as a biocompatible matrix for nasal drug delivery 
in pharmaceutical developments [1]. The aims of this work were to prepare non-cross-linked 
and cross-linked drug-free and MEL-containing chitosan-based microparticles by spray drying 
while optimizing the process parameters and the composition of the formulation. The effect 
of inlet air temperature and pump rate on the particle size distribution and morphology of 
drug-free chitosan particles was investigated to determine the optimal parameters. After that, 
the micrometric properties, structural characterization and in vitro drug release of MEL-
containing samples were studied. Sodium tripolyphosphate (TPP) was used in different 
amounts as the cross-linking agent. Micronized chitosan particles were successfully prepared 
regardless of the process parameters and the concentration of TPP. Nearly spherical habit 
could be observed in the case of drug-containing samples. The highest amount of molecularly 
dispersed MEL dissolved from the non-cross-linked formulation, controlled drug release was 
observed. Based on the mentioned results, spray-dried chitosan microparticles containing 
MEL may offer an opportunity to reduce acute pain or enhance analgesia through the nasal 
route. 
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